NCT01716806 2024-06-11A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)Seagen Inc.Phase 2 Completed131 enrolled 28 charts
NCT01644253 2021-05-20Phase 1b Safety and Efficacy Study of TRU-016Aptevo TherapeuticsPhase 1 Terminated87 enrolled